Early hypertension is associated with better clinical outcomes in gastric cancer patients treated with ramucirumab plus paclitaxel
Metrics: PDF 1096 views | HTML 1811 views | ?
Naoki Fukuda1, Daisuke Takahari1, Takeru Wakatsuki1, Hiroki Osumi1, Izuma Nakayama1, Tomohiro Matsushima1, Takashi Ichimura1, Mariko Ogura1, Masato Ozaka1, Mitsukuni Suenaga1, Eiji Shinozaki1, Keisho Chin1 and Kensei Yamaguchi1
1Department of Gastroenterology, The Cancer Institute Hospital of JFCR, Tokyo, Japan
Daisuke Takahari, email: email@example.com
Keywords: ramucirumab; gastric cancer; hypertension; paclitaxel; toxicity
Received: December 04, 2017 Accepted: February 25, 2018 Epub: March 08, 2018 Published: March 16, 2018
Anti-vascular endothelial growth factor (VEGF) therapeutics such as bevacizumab, which are widely used in cancer treatment, commonly leads to hypertension. Moreover, bevacizumab-induced hypertension is associated with improved clinical outcomes in several cancers. We retrospectively analyzed 89 patients with histologically confirmed advanced gastric cancer who received the human monoclonal anti-VEGF receptor-2 antibody ramucirumab plus paclitaxel at our hospital between June 2015 and October 2016 to evaluate the impact of treatment-associated hypertension occurring within the first two treatment cycles (“early hypertension”) on outcome. The objective response rate was 40%, median progression-free survival was 5.4 months, and overall survival was 10.4 months, which is similar to previous reports. Early hypertension in patients who received more than two cycles of ramucirumab + paclitaxel was associated with longer progression-free and overall survival. Objective response rates were also higher in patients with early hypertension. These data indicate that early hypertension may be predictive of better outcomes in gastric cancer patients who receive ramucirumab + paclitaxel treatment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.